2 citations
,
January 2025 in “Pharmaceutical Research” This article reviews the possible therapeutic activities of Angelica gigas Nakai root extracts and their components, noting their potential effects on neuro-cognitive, metabolic, and other health conditions, and reports no new clinical results.
1 citations
,
June 2023 in “Radiation oncology journal” This study suggests that low-dose radiotherapy may lead to temporary neurological improvements in some Alzheimer's patients, with 20% showing cognitive improvement at 6 months; it was well-tolerated, though larger trials are needed for confirmation.
1 citations
,
November 2008 in “Gerontology” This article discusses the increasing use of lifestyle drugs by healthy individuals to alter appearance or slow aging and emphasizes the need for doctors to consider side effects and contraindications, but it reports no new clinical findings.
April 2026 in “Frontiers in Pharmacology” This study revealed significant signals of drug-related cognitive disorders in several medications that lack relevant FDA label warnings, suggesting a need for increased clinical awareness and potential label updates.
March 2026 in “Aging Research” This review provides a comprehensive synthesis of skin aging research, highlighting the interplay of genetic and environmental factors, cellular mechanisms, and advances in diagnostic and therapeutic strategies, while also addressing current debates and future directions in the anti-aging field.
February 2026 in “Journal of Integrative Neuroscience” In this study, transplantation of hair follicle stem cells and nerve growth factor-modified stem cells significantly reduced amyloid deposition and tau hyperphosphorylation in an Alzheimer's disease rat model, suggesting potential as a treatment option.
September 2025 in “Cermin Dunia Kedokteran” This review highlights the importance of implementing dementia screening and cognitive evaluation in primary care to better prepare healthcare providers for managing cognitive impairment in the aging population.
July 2024 in “ADMET & DMPK” This review discusses the potential for surface-modified nanostructured lipid carriers to enhance hair regrowth by improving drug absorption and stability, focusing on their use with agents like minoxidil and finasteride for hair loss treatment.
February 2024 in “International Journal For Multidisciplinary Research” This review examines the advances in nanostructured lipid carriers for treating hyperpigmentation but presents no new clinical results; the authors highlight their potential benefits and applications.
January 2024 in “Scientific reports” This study found that undiluted mint leaf extract effectively inhibited multidrug-resistant Staphylococcus aureus and killed Culex pipiens larvae, suggesting its potential as a biocontrol strategy around hospitals.
January 2024 in “RSC pharmaceutics” This source discusses using stratum corneum ablation as a promising method to enhance transdermal drug delivery by temporarily removing the skin's outermost barrier to improve medication absorption.
December 2023 in “Biointerface Research in Applied Chemistry” This study used molecular docking to identify stiripentol as a potential new inhibitor of the SRD5A2 enzyme, which is targeted for treating androgen-related diseases; however, in vivo trials are needed to validate its efficacy.
August 2023 in “Natural Resources for Human Health” This paper offers a detailed overview of B vitamins, detailing their importance for energy, cognition, and metabolism, conditions leading to their deficiencies, symptoms of deficiencies, and the foods rich in these essential nutrients.
May 2021 in “Letters in Applied NanoBioScience” This study used computational methods to identify pranlukast and mirabegron as promising candidates for repurposing against diabetes due to their good binding interactions with the DPP-IV target.
This article reviews knowledge-sharing efforts in pharmaceutical sciences at the University of Sorocaba, highlighting global collaboration on rational medicine use, without reporting new study results.
This article discusses the Graduate Program in Pharmaceutical Sciences at the University of Sorocaba and emphasizes collaborating internationally to improve health policies and practices but reports no new research findings.
January 2019 in “Springer eBooks” This review discusses drugs and mechanisms possibly responsible for chemical- and drug-induced hair loss but presents no new research findings.
March 2017 in “Fundamental & Clinical Pharmacology” This case study reported an improvement in lower limb edema for a patient with type 2 diabetes mellitus after starting dulaglutide treatment, suggesting a potential role of the drug in sodium retention disorders.
November 2016 in “Therapeutic Delivery” New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.
3 citations
,
January 2016 in “Case reports in dermatological medicine” This report discusses a case of localized hypertrichosis that developed after an elderly male with Alzheimer's disease started oral rivastigmine therapy, suggesting a potential link between the drug and hair growth.
October 2015 in “Elsevier eBooks” Pramipexole can cause side effects like dizziness, sleepiness, hallucinations, and low blood pressure, and it's important to educate patients and keep doses low.
May 2011 in “Psychiatric News” This article provides regulatory updates, legal briefs, and industry news, reporting no new clinical findings.
8 citations
,
January 2016 in “Case Reports in Psychiatry” The authors report a dementia patient who developed severe trichotillomania unresponsive to SSRIs, which improved with quetiapine; they suggest dopamine blockade may manage such symptoms in dementia.
1 citations
,
February 2022 in “Brain Research Bulletin” This study found that finasteride reduced impulsivity in a rat model of pramipexole-induced probability discounting, possibly by normalizing D3 receptor expression in the nucleus accumbens.
November 2001 in “The Journal of neuropsychiatry and clinical neurosciences/The journal of neuropsychiatry and clinical neurosciences” This case report from the University of Alabama describes a rare paradoxical effect where divalproex sodium was associated with increased agitation and hostility in a patient with schizoaffective disorder.
4 citations
,
November 2001 in “Journal of Neuropsychiatry” This case report from the University of Alabama, Birmingham describes a rare paradoxical reaction of increased agitation and hyperactivity in a patient with schizoaffective disorder treated with divalproex sodium.
April 2026 in “Therapeutic Advances in Drug Safety” This study developed a new clustering model to improve detection of drug-induced cognitive disorder risk signals, finding that it identified drugs with moderate risk signals, like Carbidopa/Levodopa, missed by traditional methods, enhancing clinical assessment comprehensiveness.
16 citations
,
February 2009 in “Clinical neurology and neurosurgery” In this study, patients with epilepsy who switched from immediate-release to extended-release divalproex sodium did not experience significant changes in seizure frequency, but most preferred the new formulation due to a subjective decrease in tremor during daily activities.
7 citations
,
October 2009 in “Journal of the American Geriatrics Society” This study found that finasteride may reduce inappropriate sexual behaviors in geriatric patients with vascular dementia and benign prostate hyperplasia without serious side effects, though some patients required additional medications.
December 2013 in “Nursing2023” The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.